Breast Augmentation in HR
Breast Augmentation plastic surgery in HR section, includes general infrmation about Breast Augmentation Procedure, Breast Augmentation HR Local News, Breast Augmentation HR Surgeon Locator and other breast augmentation related materal.
HR Breast Augmentation - The Plastic Surgery Procedure
The plastic surgery operation is usually done when the breast reaches its final size after puberty (ages 17-18). Except for cases when there is congenital breast hypoplasia or breast asymmetry in which it can be done earlier (local regulations in HR may be applicable).
HR breast augmentation - the implants
There are three possible areas for the insertion of an implant for augmentation. The lower fold of the breast is the most common site. It allows full excess and lives a hidden scar. The second site is through the areola. This incision gives the best esthetic results but it is also the only one that goes through the breast tissue therefore the risk of infection and sensation loss is higher. The third one is through the armpits. Some plasit surgeons prefer it because the scar is almost invisible (except for those women who like to wear open close with no sleeves(. The disadvantage of this incision is a slight asymmetry of the breast. The decision usually made individually with each woman and the plastic surgeon (consult local HR surgeons).
The augmentation implant can be inserted above or below the chest muscles. The below position considered to be more preferable by most HR surgeons. There is less chance of feeling the implant, less chance of developing irregular folds or bumps on the surface of the breast and the implant is less likely to drop. This kind of plastic surgery technique is suitable for women with relatively little extra skin and less fallen breasts.
Most of the implants are made of silicon, and since the FDA determined that they safe for use they are being widely used by most plastic surgeons in HR.
[breast augmentation HR top]
HR breast augmentation - shape and size
The augmentation implants come in two shapes: round and pear shape also called "anatomic implants" because their shape resembles the natural contour of the breast. They are more expensive and require larger excision during the breast augmentation plastic surgery procedure.
The size of an implant usually depends on the woman size and proportions, the average size is 300cc. It is believed that smaller implants have lower complications.
[breast augmentation HR top]
HR breast augmentation - after the plastic surgery
After the augmentation plastic surgery you'll be wearing a sports bra or a bandage. You'll continue wearing them at all times day and night for about a month. You'll be able to take a shower 24 hours after the plastic surgery. The most optimal results usually seen 3 month after the surgery. Several things can complicate this plastic surgery procedure; those are rare complications, which you should be aware off. Bleeding around the area of the implant, infection, disturbances of sensation and touch around the nipples, silicon leak, rejection off an implant and some degree of irregularity on the surface of an implant.
Other Breast Augmentation Procedures
All Breast Plastic Surgery Procedures
HR Breast augmentation Plastic Surgery (current)
HR Breast Lift Plastic Surgery
HR Breast Implants Plastic Surgery
HR Implant Removal Plastic Surgery
HR Armpit Incision Plastic Surgery
More HR info...
Breast AugmentationLatest Forum Posts...
- Hello
What is new ?
Best from memola
Plastic Surgery News...
- India's Patent Office has granted Johnson & Johnson a patent for its antiretroviral drug etravirine, patent attorney Varoon Chhonkar said recently, the Economic Times reports. According to the Times, etravirine, which is marketed by J&J subsidiary Tibotec Pharmaceuticals, already has a U.S. patent and is used in the U.S.
- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) and GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to elesclomol (formerly STA-4783) for the treatment of patients with metastatic melanoma. Elesclomol is being developed under a global collaboration agreement between Synta and GSK.